Under the partnership, RPG Life Sciences will exclusively market and distribute Naprosyn ES — a combination of Naproxen and Esomeprazole — across the country, and Archerchem as the exclusive supplier, the company said in a statement.
Naprosyn ES is designed to deliver an effective anti-inflammatory solution along with gastroprotection. The combination has been co-developed by Archerchem Healthcare along with its development partner, it added.
“Naprosyn ES is an example of our strong R&D-driven approach to differentiated products, and the long-standing trust that doctors and patients place in the Naprosyn brand,” RPG Life Sciences Managing Director, Ashok Nair, said.
Archerchem Healthcare Chairman & MD Anil Dhedia said, “This partnership exemplifies Archerchem’s core strength in developing complex differential formulations.”
Through the partnership with RPG Life Sciences, which has a strong presence in multiple chronic and acute therapies, including in the pain management segment, he said, “We are proud to deliver incremental innovation that enhances medication adherence and brings meaningful benefit to patients across India.”